Liu X L, Zhao X, Wang C, Gao S J, Tan Y H
Cancer Center, The First Hospital of Jilin University, Changchun, P.R. China.
Department of Pediatrics, The First Hospital of Jilin University, Changchun, P.R. China.
J Biol Regul Homeost Agents. 2017 Jan-Mar;31(1):171-175.
Therapeutic options for patients with relapse of acute myeloid leukemia (AML) after allo-SCT are limited. Here, we present a case of a 49-year female with AML who underwent myeloablative allo-SCT from a matched sibling donor. Seven months after transplantation she developed cGVHD and suffered from extramedullary plus concurrent medullary relapse. The presence of CNS extramedullary disease is unique. Our patient was treated with decetabine. After one cycle the patient achieved complete remission and full donor chimerism without severe side effects or the occurrence of GVHD. Our case report, together with previous studies, provides strong evidence that decitabine may be a suitable treatment option for AML relapse after allogeneic transplantation, especially in patients who developed GVHD.
